
AI Co-Scientist, Not AI Scientist: Why the Name Matters
Why we put the hyphen in front of every product we build. The case, from Benchling to AlphaFold to Polanyi, for keeping the human scientist front and center.
Blog
Explore tutorials, product updates, and insights on AI-powered research automation from the K-Dense team.

Why we put the hyphen in front of every product we build. The case, from Benchling to AlphaFold to Polanyi, for keeping the human scientist front and center.

K-Dense is evaluating Nemotron 3 Nano Omni — NVIDIA's new open omni-modal model that unifies vision, audio, and language for — agentic scientific workflows.

Pantheon is a free K-Dense app that sends one research question to 80 AI personas, streaming diverse perspectives with cited sources and consensus.

Frontier LLMs are smart but generic. mimeo reads the internet on your behalf and distills how specific great minds like Jobs, Buffett, Wittgenstein, and Regev actually reason into a SKILL.md or AGENTS.md your agent can load. 80+ ready-to-use experts available today.

A skill is executable research code with a personality. Treat it accordingly. A practical guide to prompt-injection risks, poisoned SKILL.md files, auditing the scripts/ and references/ directories, the Cisco AI Defense Skill Scanner, version pinning, and a pre-install checklist every lab should adopt.

Combine NVIDIA OpenShell's policy-governed runtime with Scientific Agent Skills to run autonomous research agents that are both highly capable and genuinely safe on patient data, proprietary molecules, and HPC credentials.

Key takeaways from our April 2026 Office Hours covering open source model support, research workflows, model performance, platform comparisons, and enterprise deployment.

K-Dense Web autonomously queried 4 live databases, ran 7 Python analysis scripts, and produced a 44-page competitive intelligence report on CT-388, Roche's dual GLP-1/GIP agonist for obesity.

K-Dense Web autonomously integrated 6 databases, ranked 6 candidate biomarkers, and produced Phase III trial design recommendations for CD20xCD3 bispecific antibodies in B-cell lymphoma.